Oliveto Joseph 4/A

What Happened

• Joseph Oliveto, President, CEO and Director of Milestone Pharmaceuticals (MIST), was awarded a derivative equity grant covering 679,000 shares on February 2, 2026. The reported acquisition price is $0.00 (derivative award/option grant), and the filing on Feb 5, 2026 is an amendment that corrects the previously misstated exercise price. This transaction is an award (not a sale or open-market purchase) and does not represent an immediate cash purchase or sale.

Key Details

• Transaction date: 2026-02-02; Amendment filed: 2026-02-05 (corrects exercise price from initial filing) — see footnote F1.
• Reported amount: 679,000 shares; reported price: $0.00 (derivative award).
• Vesting: One-fourth (1/4) vests on Feb 2, 2027; then 1/36th of the remaining shares vest each month thereafter, contingent on continued service (footnote F2).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing status: Amended Form 4 (correction to exercise price). No late-timeliness flag was provided in the summary.

Context

• This is a derivative equity award (likely stock options or restricted units) rather than an immediate stock purchase or sale. No shares were reported sold or exercised in this filing; the award vests over time and may require future action (and potential payment of an exercise price) before any shares are transferable or sold. The amendment suggests the company/insider corrected an earlier reporting error about the exercise price.